MedPath

Tradipitant

Generic Name
Tradipitant
Drug Type
Small Molecule
Chemical Formula
C28H16ClF6N5O
CAS Number
622370-35-8
Unique Ingredient Identifier
NY0COC51FI
Background

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.

Clinical Trials
Related News

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Phase 3
Recruiting
Conditions
Idiopathic Gastroparesis
Diabetic Gastroparesis
Gastroparesis
Interventions
First Posted Date
2025-02-20
Last Posted Date
2025-02-20
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT06836557
Locations
πŸ‡©πŸ‡ͺ

Vanda Investigational Site, Leipzig, Germany

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Phase 2
Recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2025-02-03
Last Posted Date
2025-03-10
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT06804603
Locations
πŸ‡ΊπŸ‡Έ

Vanda Investigational Site, Rochester, Minnesota, United States

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3
Recruiting
Conditions
Motion Sickness
Interventions
First Posted Date
2023-11-18
Last Posted Date
2024-03-21
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
500
Registration Number
NCT06138613
Locations
πŸ‡ΊπŸ‡Έ

Santa Monica Clinical Trials, Santa Monica, California, United States

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3
Completed
Conditions
Motion Sickness
Interventions
Drug: Placebo
First Posted Date
2023-06-15
Last Posted Date
2025-04-04
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
316
Registration Number
NCT05903924
Locations
πŸ‡ΊπŸ‡Έ

Pacific Research Partners, San Diego, California, United States

πŸ‡ΊπŸ‡Έ

Lumos Clinical Research, San Jose, California, United States

πŸ‡ΊπŸ‡Έ

Santa Monica Clinical Trials, Santa Monica, California, United States

and more 2 locations

Tradipitant for Functional Dyspepsia

Phase 2
Conditions
Functional Dyspepsia
Interventions
Drug: Placebo
First Posted Date
2022-12-16
Last Posted Date
2025-04-21
Lead Sponsor
Xiao Jing (Iris) Wang
Target Recruit Count
60
Registration Number
NCT05653310
Locations
πŸ‡ΊπŸ‡Έ

Mayo Clinic in Minnesota, Rochester, Minnesota, United States

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
First Posted Date
2021-04-19
Last Posted Date
2024-04-16
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
27
Registration Number
NCT04849559
Locations
πŸ‡ΊπŸ‡Έ

Vanda Investigational Site, Rochester, Minnesota, United States

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Conditions
Gastroparesis
Diabetic Gastroparesis
First Posted Date
2020-07-17
Last Posted Date
2023-10-04
Lead Sponsor
Vanda Pharmaceuticals
Registration Number
NCT04474990
Locations
πŸ‡ΊπŸ‡Έ

Vanda Investigational Site, Spokane, Washington, United States

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Phase 3
Completed
Conditions
Motion Sickness
Interventions
Drug: Placebo
First Posted Date
2020-03-31
Last Posted Date
2024-12-11
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
366
Registration Number
NCT04327661
Locations
πŸ‡ΊπŸ‡Έ

Gulfcoast Psychiatric Associates, Fort Myers, Florida, United States

πŸ‡ΊπŸ‡Έ

Pacific Research Network, LLC, San Diego, California, United States

πŸ‡ΊπŸ‡Έ

Santa Monica Clinical Trials, Santa Monica, California, United States

and more 4 locations

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Phase 3
Conditions
Coronavirus Infection
Interventions
Drug: Placebo
First Posted Date
2020-03-30
Last Posted Date
2020-04-20
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
300
Registration Number
NCT04326426
Locations
πŸ‡ΊπŸ‡Έ

Lenox Hill Hospital Northwell Health, New York, New York, United States

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Phase 3
Terminated
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2019-10-28
Last Posted Date
2024-05-14
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
87
Registration Number
NCT04140695
Locations
πŸ‡ΊπŸ‡Έ

Vanda Investigational Site, Spokane, Washington, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy